Seasoned executive to lead international commercialization
SUNNYVALE, CA, June 25, 2012 /CNW/ - Viveve, Inc., a privately held
woman's health company, has announced the appointment of Patricia
Scheller as Chief Executive Officer. In addition to this position, Ms.
Scheller will also serve on Viveve's Board of Directors.
"Patricia Scheller is the perfect leader for the next stage of the
company's development," stated Brigitte Smith, Viveve's Chairman of the
Board and Managing Director of GBS Venture Partners. "Viveve is
pioneering quick and painless non-surgical treatment to address vaginal
laxity and loss of physical sensation that is common to many women
after vaginal childbirth. Patricia's experience in building global new
businesses and establishing strong market franchises will help position
the company and technology for rapid market adoption. Her impressive
track record of successful product introductions, coupled with her
management and strategic development expertise, will position Viveve
for market success."
Ms. Scheller has more than 25 years of executive marketing, business
development and managerial experience within the health care industry.
Most recently she served as CEO of Prescient Medical, Inc., a privately
held company focused on the development of diagnostic and treatment
products designed to reduce deaths from heart attacks. Prior to
working at Prescient Medical, she was the CEO of SomaLogic, Inc., a
biotechnology company focused on the development of diagnostic products
using aptamer technology. In addition, she has managed several
business units of Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson
company, and held several senior positions at Dade Behring, Inc. While
at Dade Behring, Inc., she directed the commercialization of the hsCRP
diagnostic test, a screening test for systemic inflammation, which has
been shown to increase the risk of heart attacks. The hsCRP test was
the first diagnostic test added to the cardiac test panel by the Center
for Disease Control and Prevention and American Heart Association in
over 30 years. As Director of cardiology systems at Cordis Corporation
(a Johnson & Johnson company) she managed the launch of the first
Palmaz-Schatz® balloon-expandable coronary stent, the first major
product entry into what became a $6 billion market.
"The Viveve technology has the potential to improve the lives of women
all over the world," explained Ms. Scheller. "I'm looking forward to
working with the dedicated team at Viveve and clinicians around the
world to create widespread awareness of the company's groundbreaking
technology and establishing Viveve as a leader in the women's health
About Viveve, Inc.:
Viveve is a privately held women's health company based in Sunnyvale,
California. The Viveve System is a medical device used for the
non-surgical treatment of post-partum laxity of the vaginal introitus,
a medically recognized quality of life condition. The Viveve System has
received CE Mark approval in Europe and a Medical Device License from
Health Canada allowing the product to be marketed for its intended use
in these markets. It is not currently available for sale in the U.S.
The company's Series A and Series B financing was led by GBS Venture
Partners and 5AM Ventures.
Viveve Inc is currently an associate member of the Society of
Obstetricians and Gynaecologists of Canada.
For more information, visit www.viveve.com.
SOURCE Viveve, Inc.
For further information:
or to arrange an interview, please contact:
GCI Group (Canada)